Randomized controlled trial for freezing embryo transplantation with hormone replacement cycle in the treatment of pregnancy-related venous thromboembolism

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1900028570

Enrollment

Unknown

Registered

2019-12-27

Start date

2020-01-01

Completion date

Unknown

Last updated

2020-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pregnancy-related venous thromboembolism

Interventions

HRT-FET group:Use the estrogen and progesterone control the window period of embryo implantation

NC-FET group:none

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Chinese women aged 20 to 50 years old; 2. The menstrual cycle (21 days and 35 days or less or higher); 3. Single FET embryo number 2 or less; 4. Before transplantation thrombosis assessed by the RCOG guidelines for low risk; 5. Patients or agent has signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. With ovulation disorder (such as endometriosis, polycystic ovarian syndrome); 2. With history of pregnancy complications, gestational hypertension, gestational diabetes, etc.; 3. With history of serious obstacle correlation disease or blood clotting function, severe liver and kidney function is not complete; 4. Nearly 3 month history of blood transfusion, the history of intravenous drug use, etc.; 5. After thawing there is no usable embryos; 6. Within 6 months conducted FET or prepared endometrium before FET; 7. Clinical data is not complete.

Design outcomes

Primary

Measure	Time frame
The incidence of VTE;	—

Countries

China

Contacts

Public ContactJin Lin

International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University

jinli96@shsmu.edu.cn+86 18017316196

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026